Biohaven Ltd (BHVN) concluded trading on Thursday at a closing price of $15.59, with 4.06 million shares of worth about $63.31 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -63.95% during that period and on June 12, 2025 the price saw a loss of about -0.64%. Currently the company’s common shares owned by public are about 102.10M shares, out of which, 89.17M shares are available for trading.
Stock saw a price change of -3.77% in past 5 days and over the past one month there was a price change of -20.09%. Year-to-date (YTD), BHVN shares are showing a performance of -58.26% which decreased to -55.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.33 but also hit the highest price of $55.70 during that period. The average intraday trading volume for Biohaven Ltd shares is 1.96 million. The stock is currently trading -1.52% below its 20-day simple moving average (SMA20), while that difference is down -15.44% for SMA50 and it goes to -55.91% lower than SMA200.
Biohaven Ltd (NYSE: BHVN) currently have 102.10M outstanding shares and institutions hold larger chunk of about 88.79% of that.
The stock has a current market capitalization of $1.59B and its 3Y-monthly beta is at 3.64. It has posted earnings per share of -$9.37 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BHVN, volatility over the week remained 3.14% while standing at 5.63% over the month.
Stock’s fiscal year EPS is expected to rise by 17.97% while it is estimated to increase by 16.28% in next year. EPS is likely to grow at an annualized rate of 17.19% for next 5-years, compared to annual growth of -49.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on May 19, 2025 offering a Sector perform rating for the stock and assigned a target price of $21 to it. Coverage by Deutsche Bank stated Biohaven Ltd (BHVN) stock as a Buy in their note to investors on February 11, 2025, suggesting a price target of $65 for the stock. On September 16, 2024, Jefferies Initiated their recommendations, while on September 04, 2024, Bernstein Initiated their ratings for the stock with a price target of $55. Stock get an Overweight rating from Morgan Stanley on July 24, 2024.
